Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CADLNYSEAMERICAN:MAIANASDAQ:PVLANASDAQ:SGMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCADLCandel Therapeutics$5.14+3.0%$5.23$3.79▼$14.60$257.53M-0.911.47 million shs116,257 shsMAIAMAIA Biotechnology$1.84+0.8%$1.85$1.40▼$4.24$56.07M0.03229,518 shs16,516 shsPVLAPalvella Therapeutics$24.49-1.6%$23.30$6.20▼$29.27$270.86M-0.1179,040 shs3,459 shsSGMTSagimet Biosciences$8.91+2.7%$5.34$1.73▼$10.43$273.91M3.351.08 million shs256,122 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCADLCandel Therapeutics-2.16%-1.38%-17.38%+13.67%-14.26%MAIAMAIA Biotechnology-1.08%+1.67%+1.67%+27.08%-45.05%PVLAPalvella Therapeutics+3.23%+10.47%-1.97%+21.40%+2,489,999,900.00%SGMTSagimet Biosciences+6.57%+13.91%+56.12%+356.84%+193.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCADLCandel Therapeutics2.4727 of 5 stars3.51.00.00.03.31.70.6MAIAMAIA Biotechnology0.5578 of 5 stars0.03.00.00.00.43.30.0PVLAPalvella Therapeutics3.3595 of 5 stars3.60.00.00.02.74.20.6SGMTSagimet Biosciences2.3942 of 5 stars3.52.00.00.02.52.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCADLCandel Therapeutics 3.00Buy$22.00328.02% UpsideMAIAMAIA Biotechnology 0.00N/AN/AN/APVLAPalvella Therapeutics 3.13Buy$46.2989.00% UpsideSGMTSagimet Biosciences 3.00Buy$26.60198.47% UpsideCurrent Analyst Ratings BreakdownLatest MAIA, CADL, SGMT, and PVLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$23.006/6/2025SGMTSagimet BiosciencesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $27.005/16/2025PVLAPalvella TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$53.00 ➝ $52.004/30/2025PVLAPalvella TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/11/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.004/9/2025PVLAPalvella TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCADLCandel TherapeuticsN/AN/AN/AN/A$1.41 per shareN/AMAIAMAIA BiotechnologyN/AN/AN/AN/A$0.14 per shareN/APVLAPalvella Therapeutics$42.81M6.33N/AN/A$5.58 per share4.39SGMTSagimet Biosciences$2M136.67N/AN/A$5.08 per share1.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCADLCandel Therapeutics-$55.18M-$1.34N/AN/AN/AN/A-136.74%-63.13%8/12/2025 (Estimated)MAIAMAIA Biotechnology-$23.25M-$1.38N/AN/AN/AN/A-474.86%-146.56%8/8/2025 (Estimated)PVLAPalvella Therapeutics-$17.43M-$12.10N/AN/AN/AN/A-60.29%-43.30%8/13/2025 (Estimated)SGMTSagimet Biosciences-$45.57M-$1.76N/AN/AN/AN/A-35.21%-34.09%8/13/2025 (Estimated)Latest MAIA, CADL, SGMT, and PVLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PVLAPalvella Therapeutics-$3.40-$0.74+$2.66-$0.74N/AN/A5/13/2025Q1 2025CADLCandel Therapeutics-$0.24$0.13+$0.37$0.13N/AN/A5/8/2025Q1 2025SGMTSagimet Biosciences-$0.79-$0.56+$0.23-$0.56N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCADLCandel TherapeuticsN/AN/AN/AN/AN/AMAIAMAIA BiotechnologyN/AN/AN/AN/AN/APVLAPalvella TherapeuticsN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCADLCandel Therapeutics0.014.644.64MAIAMAIA BiotechnologyN/A2.352.35PVLAPalvella TherapeuticsN/A8.848.84SGMTSagimet BiosciencesN/A20.3420.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCADLCandel Therapeutics13.93%MAIAMAIA Biotechnology5.65%PVLAPalvella Therapeutics40.11%SGMTSagimet Biosciences87.86%Insider OwnershipCompanyInsider OwnershipCADLCandel Therapeutics16.60%MAIAMAIA Biotechnology32.32%PVLAPalvella Therapeutics20.50%SGMTSagimet Biosciences14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCADLCandel Therapeutics6050.10 million41.79 millionOptionableMAIAMAIA Biotechnology930.31 million20.51 millionNot OptionablePVLAPalvella TherapeuticsN/A11.06 million8.79 millionN/ASGMTSagimet Biosciences830.67 million26.17 millionOptionableMAIA, CADL, SGMT, and PVLA HeadlinesRecent News About These CompaniesSagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Rating of "Buy" by AnalystsJuly 1, 2025 | americanbankingnews.comSagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Buy" by AnalystsJuly 1, 2025 | marketbeat.comSGMT Sagimet Biosciences Inc. - Seeking AlphaJune 28, 2025 | seekingalpha.comSagimet Biosciences Inc News (SGMT) - Investing.comJune 27, 2025 | investing.comSagimet Biosciences Inc. (SGMT) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comSagimet Biosciences Inc.June 14, 2025 | wsj.comTwo Sigma Investments LP Trims Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT)June 12, 2025 | marketbeat.comSagimet Biosciences updates executive compensationJune 12, 2025 | investing.comWhat Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?June 11, 2025 | zacks.comSagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to ...June 11, 2025 | morningstar.comMWall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should KnowJune 9, 2025 | zacks.comSagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025June 9, 2025 | globenewswire.comSagimet Biosciences Analyst RatingsJune 5, 2025 | benzinga.comSagimet Biosciences Shares Climb on Positive Clinical Trial Results for Acne TreatmentJune 4, 2025 | marketwatch.comSagimet Biosciences shares soar on positive acne treatment trial resultsJune 4, 2025 | ca.investing.comSagimet partner Ascletis announces significant Phase III acne dataJune 4, 2025 | thepharmaletter.comTSagimet Biosciences Shares Surge After Promising Phase 3 Acne Drug ResultsJune 4, 2025 | msn.comSagimet climbs as acne therapy hits main goals in late-stage trial in ChinaJune 4, 2025 | msn.comSagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock JumpsJune 4, 2025 | aol.comASagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567June 4, 2025 | seekingalpha.comSagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner AscletisJune 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMAIA, CADL, SGMT, and PVLA Company DescriptionsCandel Therapeutics NASDAQ:CADL$5.14 +0.15 (+3.01%) As of 10:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.MAIA Biotechnology NYSEAMERICAN:MAIA$1.84 +0.01 (+0.77%) As of 10:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.Palvella Therapeutics NASDAQ:PVLA$24.49 -0.41 (-1.65%) As of 10:18 AM EasternPalvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.Sagimet Biosciences NASDAQ:SGMT$8.91 +0.23 (+2.67%) As of 10:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Why Centene Stock Dropped 40% — And Whether It's a Buy Now D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
